The role of conflict of interest in reporting of scientific information

Chest

Volumn 136, Issue 1, 2009, Pages 253-259

  Irwin, Richard S ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; CLINICAL STUDY; CONFLICT OF INTEREST; INFORMATION SYSTEM; MEDICAL ETHICS; MEDICAL LITERATURE; NOTE; PRIORITY JOURNAL; RANDOMIZATION; STUDENT; TEACHER; TRAINING; TRUST;

EID: 67650792664     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-0890     Document Type: Article

References (64)

1. Irwin RS. The editorial stewardship of CHEST changes hands. Chest 2005; 128:1-3
2. AMA Manual of Style Committee. AMA manual of style: a guide for authors and editors. 10th ed. New York, NY: Oxford University Press, 2007
3. Wikepedia. Conflict of interest. Available at: http://en.wiktionary. org/wiki/conflict-of-interest. Accessed May 3, 2009
4. Hall MA, Dugan E, Zheng B, et al. Trust in physicians and medical institutions: what is it, can it be measured, and does it matter? Milbank Q 2001; 79:613-639
5. Hall MA, Weinfurt KP. Medical trust: concepts and data. Available at: http://www.iom.edu/Object.File/Master/54/832/ Hall%20IOM.ppt. Accessed May 3, 2009
6. Sim I, Chan AW, Gulmezoglu AM, et al. Clinical trial registration: transparency is the watchword. Lancet 2006; 367:1631-1633
7. Graham DJ. COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA 2006; 296:1653-1656
8. Steinman MA, Bero LA, Chren M-M, et al. Narrative review: the promotion of gabapentin; an analysis of internal industry documents. Ann Intern Med 2006; 145:284-293
9. Nylenna M, Simonsen S. Scientific misconduct: a new approach to prevention. Lancet 2006; 367:1882-1884
10. Miller FG, Brody H. Professional integrity in industry-sponsored clinical trials. Acad Med 2005; 80:899-904
11. DeAngelis CD. Impugning the integrity of medical science: the adverse effects of industry influence. JAMA 2008; 299: 1833-1835
12. Steinman MA, Shlipak MG, McPhee SJ. Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am J Med 2001; 110: 551-557
13. Blake RL, Early EK. Patient's attitudes about gifts to physicians from pharmaceutical companies. J Am Board Fam Pract 1995; 8:457-464
14. Ross DB. The FDA and the case of Ketek. N Engl J Med 2007; 356:1601-1604
15. Petersen M. Our daily meds. New York, NY: Sarah Crichton Books, 2008
16. Whittington CJ, Kendall T, Fonagy P, et al. Selective serotonin receptor inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363:1341-1345
17. Topol EJ. Failing the public health: rofecoxib, Merck, and the FDA. N Engl J Med 2004; 351:1707-1709
18. Lock S, Wells F, Farthing M. eds. Fraud and misconduct in biomedical research. London, UK: BMJ Books, 2001
19. Parry J. Korean cloning studies were fakes. BMJ 2006; 332:67
20. Bhandari M, Busse JW, Jackowski D, et al. Association between industry funding and statistically significant proindustry findings in medical and surgical randomized trials. Can Med Assoc J 2004; 170:477-480
21. Nemeroff CB, Mayberg HS, Krahl SE, et al. VNS therapy in treatment-resistant depression: clinical and putative neurobiological mechanisms. Neuropsychopharmacology 2006; 31: 1345-1355
22. Holden C. The undisclosed background of a paper on a depression treatment. Science 2006; 313:598-599
23. Institute of Medicine urges reforms at FDA. Lancet 2006; 368:1211
24. Committee on the Assessment of the US Drug Safety System. The future of drug safety: promoting and protecting the health of the public. Baciu A, Stratton K, Burke SP, eds. Washington DC: National Academies Press, 2007
25. Rochon PA, Gurwitz JH, Simms RW, et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med 1994; 154:157-163
26. Wahlbeck K, Adams C. Beyond conflict of interest: sponsored drug trials show more-favourable outcomes. BMJ 1993; 318: 465
27. Kjaergard LL, Nikolova D, Glaud C. Randomized clinical trials in hepatology: predictors of quality. Hepatology 1999; 30:1134-1138
28. Djulbegovic B, Bennett CL, Lyman G, et al. Violation of the uncertainty principle in conduct of randomized controlled trials (RCTs) of erythropoietin (EPO) [abstract]. Blood 1999; 94(suppl):399A
29. Djulbegovic B, Lacevic M, Cantor A, et al. The uncertainly principle and industry-sponsored research. Lancet 2000; 356: 635-638
30. Kjaergard LL, Als-Nielsen B. Association between competing interests and authors' conclusions: epidemiological study of randomized clinical trials published in the BMJ. BMJ 2002; 325:249-252
31. Als-Nielsen B, Chen W, Gluud C, et al. Association of funding and conclusions in randomized drug trial: a reflection of treatment effect or adverse events? JAMA 2003; 290:921-928
32. Lexchin J, Bero LA, Djulbegovic B. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326:1167-1170
33. Ridker PM, Torres J. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. JAMA 2006; 295:2270-2274
34. Miller FG, Brody H. Professional integrity in industry-sponsored clinical trials. Acad Med 2005; 80:899-904
35. Fries JF, Krishnan E. Equipoise, design bias, and randomized controlled trials: the elusive ethics of new drug development. Arthritis Res Ther 2004; 6:R250-R255
36. Baumann M, Lewis S, Gutterman D. ACCP evidence-based guideline development: a successful and transparent approach addressing conflict of interest, funding, and patient-centered recommendations. Chest 2007; 132:1015-1024
37. Clancy CM, Slutsky JR. Guidelines for guidelines. Chest 2007; 132:746-747
38. American College of Chest Physicians, Health and Science Policy Committee. Available at: http://www.chestnet.org/ education/hsp/panelSelection. php. Accessed May 3, 2009
39. Christiansen SL. Ethical and legal guidance in biomedical publishing. Chest 2008; 134:1344-1346
40. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects, amended by the 59th WMA General Assembly, Seoul, October 2008. Available at: http://www.wma.net/e/policy/b3.htm. Accessed May 3, 2009
41. Barron JP. The uniform requirements for manuscripts submitted to biomedical journals recommended by the International Committee of Medical Journal Editors. Chest 2006; 129:1098-1099
42. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals: writing and editing for biomedical publication. Available at: http://www.icmje.org. Accessed May 3, 2009
43. Council of Science Editors. CSE's white paper on promoting integrity in scientific journal publications. Available at: http:// www. councilscienceeditors.org/editorial-policies/white-paper. cfm. Accessed May 3, 2009
44. World Association of Medical Editors. Publication ethics policies for medical journals. Available at: http://www.wame. org/resources/ethics-resources/ publication-ethics-policies-formedical-journals/. Accessed May 3, 2009
45. Committee on Publication Ethics. About COPE. Available at: http://publicationethics.org/about. Accessed May 3, 2009
46. Committee on Publication Ethics. COPE flowcharts. Available at: http://publicationethics.org/flowcharts. Accessed May 3, 2009
47. Integrity in Science. The Integrity in Science database. Available at: http://www.cspinet.org/integrity/index.html. Accessed May 3, 2009
48. Kesselheim AS, Studdert DM. Whistleblower-initiated enforcement actions against health care fraud and abuse in the United States, 1996 to 2005. Ann Intern Med 2008; 149:342-349
49. Baines E. Italian doctors face fraud and murder charges. Lancet 2008; 371:2159
50. United States Code (2008) US Public Law 110-85: Food and Drug Administration Amendments Act of 2007. Available: http://frwebgate.access.gpo. gov/cgi-bin/getdoc.cgi?dbname=110-cong-public-laws&docid=f:publ085.110. Accessed May 3, 2009
51. Irwin RS. Clinical trial registration promotes patient protection and benefit, advances the trust of everyone, and is required. Chest 2007; 131:639-641
52. De Angelis C, Drazen JM, Frizelle FA, et al. Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. Ann Intern Med 2004; 141:477-478
53. Zarin DA, Keselman A. Registering a clinical trial in ClinicalTrials. gov. Chest 2007; 131:909-912
54. Tse T, Williams R, Zarin DA. Update on registration of clinical trials in ClinicalTrials.gov. Chest 2009; 136:304-305
55. Tse T, Williams RJ, Zarin DA. Reporting "basic results" in ClinicalTrials.gov. Chest 2009; 136:295-303
56. Laine C, Horton R, DeAngelis CD, et al. Clinical trial registration: looking back and moving ahead. N Engl J Med 2007; 356:2734-2736
57. World Health Organization. International clinical trials registry platform. Available at: http://who.int/ictrp/network/primary/en/ index.html. Accessed May 3, 2009
58. American College of Chest Physicians. CHEST preparation of manuscripts/instructions to authors. Available at: http://www. chestjournal.org/site/misc/ifora.xhtml. Accessed May 3, 2009
59. Campbell EG, Gruen RL, Mountford J, et al. A national survey of physician-industry relationships. N Engl J Med 2007; 356:1742-1750
60. Ross JS, Lackner JE, Lurie P, et al. Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. JAMA 2007; 297:1216-1223
61. Brennan TA, Mello MM. Sunshine laws and the pharmaceutical industry. JAMA 2007; 297:1255-1258
62. Steinbrook R. Disclosure of industry payments to physicians. N Engl J Med 2008; 359:559-561
63. Cain DM, Detsky AS. Everyone's a little bit biased (even physicians). JAMA 2008; 299:2893-2895
64. Angell M. Industry-sponsored clinical research: a broken system. JAMA 2008; 300:1069-1071